![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ELP4 |
Gene summary for ELP4 |
![]() |
Gene information | Species | Human | Gene symbol | ELP4 | Gene ID | 26610 |
Gene name | elongator acetyltransferase complex subunit 4 | |
Gene Alias | AN | |
Cytomap | 11p13 | |
Gene Type | protein-coding | GO ID | GO:0002097 | UniProtAcc | Q96EB1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26610 | ELP4 | CCI_2 | Human | Cervix | CC | 9.31e-04 | 5.69e-01 | 0.5249 |
26610 | ELP4 | CCI_3 | Human | Cervix | CC | 1.04e-20 | 8.65e-01 | 0.516 |
26610 | ELP4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.42e-17 | -5.92e-01 | 0.0155 |
26610 | ELP4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.82e-11 | -6.24e-01 | -0.1808 |
26610 | ELP4 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.50e-03 | -3.49e-01 | -0.0811 |
26610 | ELP4 | HTA11_78_2000001011 | Human | Colorectum | AD | 7.77e-06 | -4.75e-01 | -0.1088 |
26610 | ELP4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.77e-06 | -5.74e-01 | -0.1207 |
26610 | ELP4 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.37e-17 | -4.80e-01 | -0.1464 |
26610 | ELP4 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.36e-12 | -4.72e-01 | -0.1001 |
26610 | ELP4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.97e-04 | -4.39e-01 | -0.059 |
26610 | ELP4 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.95e-03 | -6.56e-01 | -0.2061 |
26610 | ELP4 | HTA11_546_2000001011 | Human | Colorectum | AD | 5.63e-05 | -6.11e-01 | -0.0842 |
26610 | ELP4 | HTA11_7862_2000001011 | Human | Colorectum | AD | 5.84e-03 | -5.70e-01 | -0.0179 |
26610 | ELP4 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.53e-11 | -5.37e-01 | 0.096 |
26610 | ELP4 | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.88e-02 | -5.91e-01 | 0.0528 |
26610 | ELP4 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.67e-08 | -5.57e-01 | 0.0338 |
26610 | ELP4 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.29e-17 | -5.46e-01 | 0.0674 |
26610 | ELP4 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.01e-06 | -6.11e-01 | 0.0588 |
26610 | ELP4 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.46e-20 | -5.88e-01 | 0.294 |
26610 | ELP4 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.48e-16 | -5.39e-01 | 0.3859 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00063684 | Cervix | CC | transcription elongation from RNA polymerase II promoter | 17/2311 | 69/18723 | 3.65e-03 | 2.33e-02 | 17 |
GO:00063545 | Cervix | CC | DNA-templated transcription, elongation | 20/2311 | 91/18723 | 6.88e-03 | 3.74e-02 | 20 |
GO:0006354 | Colorectum | AD | DNA-templated transcription, elongation | 31/3918 | 91/18723 | 2.46e-03 | 1.90e-02 | 31 |
GO:0006368 | Colorectum | AD | transcription elongation from RNA polymerase II promoter | 24/3918 | 69/18723 | 5.35e-03 | 3.52e-02 | 24 |
GO:00063541 | Colorectum | MSS | DNA-templated transcription, elongation | 29/3467 | 91/18723 | 1.52e-03 | 1.39e-02 | 29 |
GO:00063681 | Colorectum | MSS | transcription elongation from RNA polymerase II promoter | 22/3467 | 69/18723 | 5.31e-03 | 3.62e-02 | 22 |
GO:00063682 | Colorectum | FAP | transcription elongation from RNA polymerase II promoter | 20/2622 | 69/18723 | 9.25e-04 | 9.26e-03 | 20 |
GO:00063542 | Colorectum | FAP | DNA-templated transcription, elongation | 24/2622 | 91/18723 | 1.32e-03 | 1.22e-02 | 24 |
GO:00063543 | Colorectum | CRC | DNA-templated transcription, elongation | 19/2078 | 91/18723 | 4.74e-03 | 3.67e-02 | 19 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
GO:000636814 | Esophagus | ESCC | transcription elongation from RNA polymerase II promoter | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
GO:00064002 | Esophagus | ESCC | tRNA modification | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
GO:00063547 | Oral cavity | OSCC | DNA-templated transcription, elongation | 63/7305 | 91/18723 | 4.86e-09 | 1.07e-07 | 63 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ELP4 | SNV | Missense_Mutation | rs764805051 | c.946N>T | p.Arg316Cys | p.R316C | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ELP4 | SNV | Missense_Mutation | rs749842817 | c.947N>A | p.Arg316His | p.R316H | protein_coding | deleterious(0.04) | benign(0.14) | TCGA-SL-A6JA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ELP4 | insertion | Frame_Shift_Ins | novel | c.478_479insCAAGTATAATACAAACATTTAAGTT | p.Ile160ThrfsTer34 | p.I160Tfs*34 | protein_coding | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |||
ELP4 | SNV | Missense_Mutation | rs764805051 | c.946N>T | p.Arg316Cys | p.R316C | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-DD-AAD3-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ELP4 | SNV | Missense_Mutation | novel | c.821A>C | p.Asn274Thr | p.N274T | protein_coding | tolerated(0.21) | benign(0.05) | TCGA-DD-AADR-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
ELP4 | SNV | Missense_Mutation | c.164N>T | p.Ser55Leu | p.S55L | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-05-4250-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
ELP4 | SNV | Missense_Mutation | c.964N>T | p.Asp322Tyr | p.D322Y | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-05-4418-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
ELP4 | SNV | Missense_Mutation | c.1468C>T | p.His490Tyr | p.H490Y | protein_coding | possibly_damaging(0.889) | TCGA-05-5425-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | gefitinib | PD | |||
ELP4 | SNV | Missense_Mutation | c.13N>T | p.Ala5Ser | p.A5S | protein_coding | deleterious_low_confidence(0.03) | benign(0.013) | TCGA-38-4625-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ELP4 | SNV | Missense_Mutation | c.1085N>G | p.Asp362Gly | p.D362G | protein_coding | tolerated(0.19) | possibly_damaging(0.81) | TCGA-49-AAR9-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |